特应性皮炎：度普利尤单抗治疗失败后使用曲罗芦单抗的真实生活经验：病例系列 - Suppr

Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series.

作者信息

Amoedo Patrícia, Rosa Gilberto, Baudrier Teresa, Pedrosa Ana Filipa, Cruz Maria João

机构信息

Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, Porto, Portugal.

Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, Porto, Portugal; Faculty of Medicine, Universidade do Porto, Porto, Portugal; Centro de Investigação em Tecnologias e Serviços de Saúde, CINTESIS, Porto, Portugal.

出版信息

An Bras Dermatol. 2024 Sep-Oct;99(5):721-724. doi: 10.1016/j.abd.2023.09.009. Epub 2024 Jun 3.

DOI:10.1016/j.abd.2023.09.009

PMID:38834396

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11342987/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4c/11342987/42085b27d41a/gr1.jpg

相似文献

Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series.特应性皮炎：度普利尤单抗治疗失败后使用曲罗芦单抗的真实生活经验：病例系列

An Bras Dermatol. 2024 Sep-Oct;99(5):721-724. doi: 10.1016/j.abd.2023.09.009. Epub 2024 Jun 3.

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.湿疹面积和严重程度指数（EASI）与改良湿疹面积和严重程度指数（p-EASI）：使用血清生物标志物组合预测接受度普利尤单抗治疗的特应性皮炎患者的疾病严重程度

Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24.

Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.阿布昔替尼用于从度普利尤单抗和/或曲罗芦单抗转换过来的中度至重度特应性皮炎患者治疗的有效性：一项真实世界回顾性研究。

J Am Acad Dermatol. 2024 Oct;91(4):734-735. doi: 10.1016/j.jaad.2024.05.081. Epub 2024 Jun 9.

Systemic Biologic Management of Atopic Dermatitis.特应性皮炎的全身性生物治疗管理。

Adv Exp Med Biol. 2024;1447:139-149. doi: 10.1007/978-3-031-54513-9_13.

Allergic contact dermatitis to Compositae: A possible cause of dupilumab-associated facial and neck dermatitis in atopic dermatitis patients?对菊科植物的过敏性接触性皮炎：特应性皮炎患者中 dupilumab 相关面部和颈部皮炎的一个可能原因？

Contact Dermatitis. 2021 Oct;85(4):473-474. doi: 10.1111/cod.13898. Epub 2021 May 27.

[Current and upcoming treatments of adult atopic dermatitis].[成人特应性皮炎的当前及未来治疗方法]

Ann Dermatol Venereol. 2017 Dec;144 Suppl 5:VS29-VS37. doi: 10.1016/S0151-9638(18)30089-9.

Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.真实世界中成人特应性皮炎患者接受度普利尤单抗治疗的经验：患者病历的回顾性分析。

Int J Dermatol. 2020 Feb;59(2):253-256. doi: 10.1111/ijd.14573. Epub 2019 Jul 8.

Alopecia Universalis and Atopic Dermatitis Improvement with Dupilumab: Demonstration of a Shared Pathophysiology and Clinical Efficacy.度普利尤单抗改善全秃和特应性皮炎：共同病理生理学及临床疗效的证明

Skinmed. 2019 May 29;17(2):139-140. eCollection 2019.

A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis.对患有过敏性接触性皮炎的特应性皮炎患者使用度普利尤单抗的回顾性研究。

J Am Acad Dermatol. 2019 Apr;80(4):1166-1167. doi: 10.1016/j.jaad.2018.12.048. Epub 2019 Jan 8.

Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.对度普利尤单抗和JAK抑制剂无反应、不耐受或有禁忌证的患者使用曲罗芦单抗治疗取得成功：病例系列报告

J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e852-e854. doi: 10.1111/jdv.19929. Epub 2024 Feb 29.

引用本文的文献

Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study.曲罗芦单抗在不同表型特应性皮炎中的有效性：一项真实世界研究。

Dermatol Ther (Heidelb). 2025 Feb;15(2):337-350. doi: 10.1007/s13555-025-01341-1. Epub 2025 Jan 25.

本文引用的文献

Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results.在临床实践中用特利鲁单抗治疗重度特应性皮炎：短期疗效和安全性结果。

Clin Exp Dermatol. 2023 Aug 25;48(9):991-997. doi: 10.1093/ced/llad153.

Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice.在日常实践中，使用曲罗芦单抗治疗中重度特应性皮炎患者。

Clin Exp Dermatol. 2023 Apr 27;48(5):510-517. doi: 10.1093/ced/llad038.

The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective.特应性皮炎生物治疗的发展现状：现状与未来展望。

Clin Exp Allergy. 2023 Feb;53(2):156-172. doi: 10.1111/cea.14263. Epub 2023 Jan 18.

Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study.曲罗芦单抗治疗难治性特应性皮炎：一项开放标签的回顾性病例系列研究。

J Eur Acad Dermatol Venereol. 2023 May;37(5):e644-e645. doi: 10.1111/jdv.18753. Epub 2022 Nov 26.

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.特罗利单抗治疗中重度特应性皮炎成人患者的 2 年长期安全性和疗效：ECZTEND 开放标签扩展试验的中期分析。

J Am Acad Dermatol. 2022 Oct;87(4):815-824. doi: 10.1016/j.jaad.2022.07.019. Epub 2022 Jul 19.

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.特利鲁单抗联合必要时的局部皮质类固醇在 32 周内为中重度特应性皮炎成人提供渐进和持续的疗效：ECZTRA 3 的事后分析。

Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20.

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.专家视角：影响中重度特应性皮炎随机临床试验结果解读的关键参数

Am J Clin Dermatol. 2022 Jan;23(1):1-11. doi: 10.1007/s40257-021-00639-y. Epub 2021 Oct 26.

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.特利鲁单抗联合局部皮质类固醇治疗中重度特应性皮炎：来自双盲、随机、多中心、安慰剂对照 III 期 ECZTRA 3 试验的结果。

Br J Dermatol. 2021 Mar;184(3):450-463. doi: 10.1111/bjd.19573. Epub 2021 Feb 22.

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).特利鲁单抗治疗中重度特应性皮炎的两项 52 周、随机、双盲、多中心、安慰剂对照 III 期临床试验（ECZTRA1 和 ECZTRA2）结果。

Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30.

Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis.白细胞介素-13：靶向特应性皮炎中被低估的细胞因子。

Allergy. 2020 Jan;75(1):54-62. doi: 10.1111/all.13954. Epub 2019 Jul 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献